The Impact of LY2189265 Versus Insulin Glargine in Combination With Insulin Lispro for the Treatment to Target of Type 2 Diabetes Mellitus
Latest Information Update: 07 Oct 2021
At a glance
- Drugs Dulaglutide (Primary) ; Insulin glargine; Insulin lispro
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms AWARD-4
- Sponsors Eli Lilly and Company
- 15 Sep 2017 Results of pooled post-hoc analysis of AWARD-2,4 and 5 , presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes.
- 15 Sep 2017 Results of post hoc subgroup (by age, duration of diabetes and baseline HbA1c) analysis assessing safety and efficacy using patient data pooled from AWARD-4 and AWARD-9 trials presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
- 13 Jun 2017 Results of a pooled post-hoc analysis of AWARD-4 and AWARD-9 studies, presented at the 77th Annual Scientific Sessions of the American Diabetes Association.